Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion

Journal of Immunology

Volumn 191, Issue 10, 2013, Pages 5005-5012

  Tel, Jurjen ^a   Sittig, Simone P ^a   Blom, Rebecca A M ^a   Cruz, Luis J ^a,b   Schreibelt, Gerty ^a   Figdor, Carl G ^a   De Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ANTIGEN; BETA1 INTERFERON; DEC 205; DENDRITIC CELL ANTIGEN 2; DENDRITIC CELL IMMUNORECEPTOR; FC RECEPTOR IIA; INTERFERON; INTERLEUKIN 6; LECTIN; LYMPHOCYTE RECEPTOR; NANOPARTICLE; POLYGLACTIN; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; TLR7 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; ENDOSOME; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; NANOENCAPSULATION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; PROTEIN TRANSPORT; TARGET CELL; DENDRITIC CELL; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS);

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; IMIDAZOLES; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; NANOPARTICLES; TOLL-LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887494213     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300787     Document Type: Article

References (50)

1. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919-923.
2. Kadowaki, N., S. Antonenko, and Y. J. Liu. 2001. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2291-2295.
3. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virusinduced type I interferon. Nat. Immunol. 4:1009-1015.
4. Ito, T., S. Hanabuchi, Y. H. Wang, W. R. Park, K. Arima, L. Bover, F. X. Qin, M. Gilliet, and Y. J. Liu. 2008. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28:870-880.
5. Schreibelt, G., J. Tel, K. H. Sliepen, D. Benitez-Ribas, C. G. Figdor, G. J. Adema, and I. J. De Vries. 2010. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59:1573-1582.
6. Benitez-Ribas, D., P. Tacken, C. J. A. Punt, I. J. M. De Vries, and C. G. Figdor. 2008. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II. J. Immunol. 181:5219-5224.
7. Meyer-Wentrup, F., D. Benitez-Ribas, P. J. Tacken, C. J. A. Punt, C. G. Figdor, I. J. M. De Vries, and G. J. Adema. 2008. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111:4245-4253.
8. Tel, J., D. Benitez-Ribas, S. Hoosemans, A. Cambi, G. J. Adema, C. G. Figdor, P. J. Tacken, and I. J. De Vries. 2011. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur. J. Immunol. 41:1014-1023.
9. Hoeffel, G., A. C. Ripoche, D. Matheoud, M. Nascimbeni, N. Escriou, P. Lebon, F. Heshmati, J. G. Guillet, M. Gannagé, S. Caillat-Zucman, et al. 2007. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 27:481-492.
10. Di Pucchio, T., B. Chatterjee, A. Smed-Sörensen, S. Clayton, A. Palazzo, M. Montes, Y. Xue, I. Mellman, J. Banchereau, and J. E. Connolly. 2008. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat. Immunol. 9:551-557.
11. Lui, G., O. Manches, J. Angel, J. P. Molens, L. Chaperot, and J. Plumas. 2009. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenzavirus exposed cells. PLoS ONE 4:e7111.
12. Schnurr, M., Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I. D. Davis, et al. 2005. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465-2472.
13. Mittag, D., A. I. Proietto, T. Loudovaris, S. I. Mannering, D. Vremec, K. Shortman, L. Wu, and L. C. Harrison. 2011. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J. Immunol. 186:6207-6217.
14. Tel, J., G. Schreibelt, S. P. Sittig, T. S. M. Mathan, S. I. Buschow, L. J. Cruz, A. J. Lambeck, C. G. Figdor, and I. J. M. De Vries. 2013. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121:459-467.
15. Tel, J., E. H. Aarntzen, T. Baba, G. Schreibelt, B. M. Schulte, D. Benitez-Ribas, O. C. Boerman, S. Croockewit, W. J. Oyen, M. Van Rossum, et al. 2013. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73:1063-1075.
16. Tacken, P. J., I. J. De Vries, R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7:790-802.
17. Tel, J., A. M. Van Der Leun, C. G. Figdor, R. Torensma, and I. J. De Vries. 2012. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol. Immunother. 61:1279-1288.
18. Zhang, J., A. Raper, N. Sugita, R. Hingorani, M. Salio, M. J. Palmowski, V. Cerundolo, and P. R. Crocker. 2006. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107:3600-3608.
19. Loschko, J., A. Schlitzer, D. Dudziak, I. Drexler, N. Sandholzer, C. Bourquin, W. Reindl, and A. B. Krug. 2011. Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. J. Immunol. 186:6718-6725.
20. Fitzgerald-Bocarsly, P., and E. S. Jacobs. 2010. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J. Leukoc. Biol. 87:609-620.
21. Blasius, A. L., E. Giurisato, M. Cella, R. D. Schreiber, A. S. Shaw, and M. Colonna. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177:3260-3265.
22. Hamdy, S., A. Haddadi, R. W. Hung, and A. Lavasanifar. 2011. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Deliv. Rev. 63:943-955.
23. Cruz, L. J., P. J. Tacken, R. Fokkink, B. Joosten, M. C. Stuart, F. Albericio, R. Torensma, and C. G. Figdor. 2010. Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144:118-126.
24. Tel, J., A. J. Lambeck, L. J. Cruz, P. J. Tacken, I. J. De Vries, and C. G. Figdor. 2010. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J. Immunol. 184:4276-4283.
25. Cruz, L. J., P. J. Tacken, J. M. Pots, R. Torensma, S. I. Buschow, and C. G. Figdor. 2012. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 33:4229-4239.
26. Schaft, N., J. Dörrie, I. Müller, V. Beck, S. Baumann, T. Schunder, E. Kämpgen, and G. Schuler. 2006. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol. Immunother. 55:1132-1141.
27. Schreibelt, G., D. Benitez-Ribas, D. Schuurhuis, A. J. Lambeck, M. Van Hout-Kuijer, N. Schaft, C. J. Punt, C. G. Figdor, G. J. Adema, and I. J. De Vries. 2010. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116:564-574.
28. Kurts, C., B. W. Robinson, and P. A. Knolle. 2010. Cross-priming in health and disease. Nat. Rev. Immunol. 10:403-414.
29. Kool, M., C. Geurtsvankessel, F. Muskens, F. B. Madeira, M. Van Nimwegen, H. Kuipers, K. Thielemans, H. C. Hoogsteden, H. Hammad, and B. N. Lambrecht. 2011. Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs. J. Leukoc. Biol. 90:1177-1190.
30. Wu, P., J. Wu, S. Liu, X. Han, J. Lu, Y. Shi, J. Wang, L. Lu, and X. Cao. 2008. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin. Immunol. 129:40-48.
31. Krug, A., R. Veeraswamy, A. Pekosz, O. Kanagawa, E. R. Unanue, M. Colonna, and M. Cella. 2003. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med. 197:899-906.
32. Boonstra, A., C. Asselin-Paturel, M. Gilliet, C. Crain, G. Trinchieri, Y. J. Liu, and A. O'Garra. 2003. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197:101-109.
33. Tacken, P. J., R. Torensma, and C. G. Figdor. 2006. Targeting antigens to dendritic cells in vivo. Immunobiology 211:599-608.
34. Schlosser, E., M. Mueller, S. Fischer, S. Basta, D. H. Busch, B. Gander, and M. Groettrup. 2008. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26:1626-1637.
35. Heit, A., F. Schmitz, M. O'Keeffe, C. Staib, D. H. Busch, H. Wagner, and K. M. Huster. 2005. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174:4373-4380.
36. Tel, J., N. Beenhakker, G. Koopman, B. Hart, G. C. Mudde, and I. J. De Vries. 2012. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNa secretion. Immunobiology 217:1017-1024.
37. Båve, U., M. Magnusson, M. L. Eloranta, A. Perers, G. V. Alm, and L. Rönnblom. 2003. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171:3296-3302.
38. Cao, W., L. Zhang, D. B. Rosen, L. Bover, G. Watanabe, M. Bao, L. L. Lanier, and Y. J. Liu. 2007. BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol. 5:e248.
39. Swiecki, M., and M. Colonna. 2010. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234:142-162.
40. Dzionek, A., Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Günther, I. Johnston, A. Lanzavecchia, T. Nagasaka, et al. 2001. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 194:1823-1834.
41. Kato, M., K. J. McDonald, S. Khan, I. L. Ross, S. Vuckovic, K. Chen, D. Munster, K. P. MacDonald, and D. N. Hart. 2006. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 18:857-869.
42. Fanger, N. A., K. Wardwell, L. Shen, T. F. Tedder, and P. M. Guyre. 1996. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 157:541-548.
43. Klechevsky, E., A. L. Flamar, Y. Cao, J. P. Blanck, M. Liu, A. O'Bar, O. Agouna-Deciat, P. Klucar, L. Thompson-Snipes, S. Zurawski, et al. 2010. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116:1685-1697.
44. Jensen, T. O., H. Schmidt, H. J. Møller, F. Donskov, M. Høyer, P. Sjoegren, I. J. Christensen, and T. Steiniche. 2012. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118:2476-2485.
45. Tacken, P. J., I. S. Zeelenberg, L. J. Cruz, M. A. Van Hout-Kuijer, G. Van De Glind, R. G. Fokkink, A. J. Lambeck, and C. G. Figdor. 2011. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118:6836-6844.
46. Pockros, P. J., D. Guyader, H. Patton, M. J. Tong, T. Wright, J. G. McHutchison, and T. C. Meng. 2007. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 47:174-182.
47. Piccioli, D., C. Sammicheli, S. Tavarini, S. Nuti, E. Frigimelica, A. G. O. Manetti, A. Nuccitelli, S. Aprea, S. Valentini, E. Borgogni, et al. 2009. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 113:4232-4239.
48. Nierkens, S., M. H. Den Brok, Z. Garcia, S. Togher, J. Wagenaars, M. Wassink, L. Boon, T. J. Ruers, C. G. Figdor, S. P. Schoenberger, et al. 2011. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 71:6428-6437.
49. Kramer, M., B. M. Schulte, D. Eleveld-Trancikova, M. Van Hout-Kuijer, L. W. Toonen, J. Tel, I. J. De Vries, F. J. Van Kuppeveld, B. J. Jansen, and G. J. Adema. 2010. Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inhibits picornavirus infection. J. Innate Immun. 2:360-370.
50. Lou, Y., C. Liu, G. J. Kim, Y. J. Liu, P. Hwu, and G. Wang. 2007. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigenspecific antitumor immune responses. J. Immunol. 178:1534-1541.